Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Core Viewpoint - Arvinas, Inc. is advancing its investigational drug ARV-393, a PROTAC designed to degrade the BCL6 protein, which is a significant driver of B-cell lymphomas, and will present preclinical data in December 2025 at the ASH Annual Meeting [1][3]. Group 1: About ARV-393 - ARV-393 targets the BCL6 protein, which plays a crucial role in B-cell lymphoma by repressing cell cycle checkpoints and apoptosis, making it a challenging target for traditional therapies [3]. - The drug is currently in a Phase 1 clinical trial for patients with non-Hodgkin lymphoma, indicating its potential therapeutic application in this area [3]. Group 2: About Arvinas - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize its PROTAC platform to selectively degrade disease-causing proteins [4]. - The company is also developing other investigational drugs, including ARV-102 for neurodegenerative disorders, ARV-806 for mutated cancers, and vepdegestrant for ER+/HER2-breast cancer [4].